Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Abstract Background Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with 177Lu-PSMA-617 for metastatic castration-resistant prostate cance...

Full description

Bibliographic Details
Main Authors: Daniel Groener, Cam Tu Nguyen, Justus Baumgarten, Benjamin Bockisch, Karen Davis, Christian Happel, Nicolai Mader, Christina Nguyen Ngoc, Jennifer Wichert, Severine Banek, Philipp Mandel, Felix K. H. Chun, Nikolaos Tselis, Frank Grünwald, Amir Sabet
Format: Article
Language:English
Published: SpringerOpen 2021-07-01
Series:EJNMMI Research
Subjects:
PSMA
177Lu-PSMA-617
Hematologic adverse events
Hematotoxicity
Metastatic castration-resistant prostate cancer
Online Access:https://doi.org/10.1186/s13550-021-00805-7

Internet

https://doi.org/10.1186/s13550-021-00805-7

Similar Items